PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32184566-9 2020 Results: The results showed that HMGR was up-regulated in the lovastatin group on day 9 and 21 compared to the control. Lovastatin 62-72 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 33-37 3851809-1 1985 Mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, stimulates neurite outgrowth and acetylcholinesterase (ACE) activity in C1300 (Neuro-2A) murine neuroblastoma cells. Lovastatin 0-9 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 38-95 6903572-1 1980 Compactin (ML-236B) and the related compound, mevinolin, are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), the rate-controlling enzyme in cholesterol synthesis. Lovastatin 46-55 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 136-153 6903572-5 1980 Administration of mevinolin to mice on a control diet produced a 6- to 10-fold increase in the amount of HMG CoA reductase in liver microsomes. Lovastatin 18-27 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 105-122 6903572-7 1980 The administration of mevinolin to cholesterol-fed mice produced a three to eightfold increase in HMG CoA reductase. Lovastatin 22-31 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 98-115 6903572-8 1980 Despite the abundant amount of cholesterol that was already present in the livers of the mevinolin-treated, cholesterol-fed animals, their elevated HMG CoA reductase could be rapidly suppressed by the subcutaneous injection of small amounts of mevalonate, the product of HMG CoA reductase. Lovastatin 89-98 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 148-165 6903572-8 1980 Despite the abundant amount of cholesterol that was already present in the livers of the mevinolin-treated, cholesterol-fed animals, their elevated HMG CoA reductase could be rapidly suppressed by the subcutaneous injection of small amounts of mevalonate, the product of HMG CoA reductase. Lovastatin 89-98 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 271-288 6903572-11 1980 The ability to suppress the elevated HMG CoA reductase with mevalonate may prove useful in potentiating the effectiveness of mevinolin as a hypocholesterolemic agent. Lovastatin 125-134 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 37-54 2722887-4 1989 However, incubation of cells with lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, for as little as 1 h prior to addition of cycloheximide rendered the isoprenylation step insensitive to cycloheximide. Lovastatin 34-44 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 73-130 3040778-8 1987 By treating 3T3 cells stimulated to resume proliferation by addition of conditioned media with mevinolin (a competitive inhibitor of HMG CoA reductase) the activity of HMG CoA reductase as well as the DNA synthesis and cell division were efficiently inhibited. Lovastatin 95-104 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 133-150 3040778-8 1987 By treating 3T3 cells stimulated to resume proliferation by addition of conditioned media with mevinolin (a competitive inhibitor of HMG CoA reductase) the activity of HMG CoA reductase as well as the DNA synthesis and cell division were efficiently inhibited. Lovastatin 95-104 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 168-185 33740503-6 2021 Conversely, ALDH2 mutant or ALDH2 deficiency in AKI or AKO mice stabilizes HMGCR, resulting in enhanced cholesterol synthesis, which can be reversed by Lovastatin. Lovastatin 152-162 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 75-80 31599189-6 2019 By using chemically distinct statins, HMGCR depletion or supplementing mevalonate, the product of HMGCR, we showed the inhibitory effects on DNA repair process of lovastatin were due to the blockage of the mevalonate pathway. Lovastatin 163-173 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 38-43 31599189-6 2019 By using chemically distinct statins, HMGCR depletion or supplementing mevalonate, the product of HMGCR, we showed the inhibitory effects on DNA repair process of lovastatin were due to the blockage of the mevalonate pathway. Lovastatin 163-173 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 98-103 31599189-8 2019 Moreover, HMGCR ablation repressed tumor growth in vivo, which can be rescued partially by restored expression of HMGCR, suggesting the on-target effects of lovastatin. Lovastatin 157-167 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 10-15 31599189-8 2019 Moreover, HMGCR ablation repressed tumor growth in vivo, which can be rescued partially by restored expression of HMGCR, suggesting the on-target effects of lovastatin. Lovastatin 157-167 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 114-119 23352156-3 2013 (2013), in this issue, demonstrates that the HMG-CoA reductase inhibitor lovastatin can normalize protein synthesis and also reduce audiogenic seizures in Fmr1 knockout mice. Lovastatin 73-83 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 45-62 27884413-9 2016 In contrast, mevalonate, but not rosiglitazone, reversed the effects of lovastatin, a competitive inhibitor of HMG CoA reductase shown to inhibit adipocyte differentiation via mevalonate deprivation. Lovastatin 72-82 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 111-128 27277576-5 2016 As expected, the use of lovastatin and orlistat significantly reduced HMGCoAR and FAS enzymatic activities and gene expression in colonic tissues, but did not affect the number of intestinal polyps, while there was a statistically significant reduction in polyp volume only in the mouse group treated with lovastatin. Lovastatin 24-34 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 70-77 27129778-6 2016 Characterization of transgenic mice revealed that HMGCR (TM1-8) is appropriately regulated in the liver of mice fed a high cholesterol diet or chow diet supplemented with the HMGCR inhibitor lovastatin. Lovastatin 191-201 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 50-55 27129778-6 2016 Characterization of transgenic mice revealed that HMGCR (TM1-8) is appropriately regulated in the liver of mice fed a high cholesterol diet or chow diet supplemented with the HMGCR inhibitor lovastatin. Lovastatin 191-201 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 175-180 16271875-0 2005 The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Lovastatin 32-42 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 4-21 20404351-6 2010 When SCARB1(-/-) mice were treated with a combination of mevinolin [an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR)] and chloroquine (an inhibitor of lysosomal processing of low-density lipoproteins), serum progesterone was further reduced. Lovastatin 57-66 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 84-124 21751201-6 2012 RESULTS: Combined apomine and lovastatin strongly decreased HMG-CoA reductase enzyme levels compared with lovastatin treatment alone. Lovastatin 30-40 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 60-77 16203826-5 2006 Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis. Lovastatin 183-193 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 126-172 16271875-5 2005 Lovastatin is a specific inhibitor of three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, used commonly for the treatment of hypercholesterolemia. Lovastatin 0-10 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 81-99 15699169-2 2005 In an acute mouse model of autoimmune retinal disease, we demonstrate that treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, lovastatin, suppresses clinical ocular pathology, retinal vascular leakage, and leukocytic infiltration into the retina. Lovastatin 153-163 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 94-141 15605420-1 2005 The statins (including mevastatin and lovastatin) are a widely prescribed class of serum-cholesterol lowering drugs that function by inhibiting 3-hydroxymethylglutaryl coenzyme A (HMG CoA) reductase activity and cellular sterol synthesis. Lovastatin 38-48 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 144-198 9802623-1 1998 Lovastatin, a fungal antibiotic used in the treatment of hypercholesterolemia, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the key regulatory enzyme in the mevalonate pathway of cholesterol synthesis. Lovastatin 0-10 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 98-145 11908910-2 2002 Treatment of cells with lovastatin, a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, depletes cells of mevalonic acid and thus blocks the isoprenylation of proteins in the RAS superfamily. Lovastatin 24-34 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 38-90 8773465-1 1996 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, inhibits the synthesis of mevalonic acid. Lovastatin 0-10 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 14-61 7475995-1 1995 Pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, exhibits liver-selectivity in inhibiting sterol synthesis, when administered as a single oral dose to mice or rats, whereas lovastatin and simvastatin do not. Lovastatin 205-215 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 29-79 7487365-1 1994 We assessed the antiproliferative effect of tumor necrosis factor alpha (TNF-alpha) and lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, alone and in combination, on two murine tumor cell lines. Lovastatin 88-98 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 116-173 8010162-1 1994 Treatment with mevinolin, a competitive inhibitor of HMGCoAR, the key enzyme of isoprenoid metabolism, causes the arrest of proliferation and the differentiation of a neuroblastoma cell line (N18TG2). Lovastatin 15-24 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 53-60 8010162-3 1994 Cholesterol synthesis in the presence of mevinolin remains active, because in these cells the key enzyme HMG-CoA reductase is not completely inhibited by this drug. Lovastatin 41-50 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 105-122 1311272-2 1992 Mevinolin is known to inhibit 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase (EC 1.1.1.34), the rate-limiting step in cholesterol biosynthesis. Lovastatin 0-9 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 30-80 8345219-2 1993 Moreover, blockade of synthesis of these lipids with inhibitors of two of the rate-limiting enzymes, HMGCoA reductase (lovastatin, fluvastatin) and serine palmitoyl transferase (beta-chloroalanine), alters the kinetics of barrier repair. Lovastatin 119-129 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 101-117 7860224-1 1993 Lovastatin (LST) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme that regulates the biosynthesis of cholesterol. Lovastatin 0-10 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 36-93 7860224-1 1993 Lovastatin (LST) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme that regulates the biosynthesis of cholesterol. Lovastatin 12-15 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 36-93 2243142-4 1990 Here we show that topical lovastatin, a competitive inhibitor of HMG CoA reductase, inhibits cholesterol synthesis. Lovastatin 26-36 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 65-82 2243142-6 1990 When lovastatin animals are simultaneously treated topically with either mevalonate, the immediate product of HMG CoA reductase, or cholesterol, the final end product of the pathway, the recovery of the barrier is normalized. Lovastatin 5-15 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 110-127